NASDAQ: TSBX - Turnstone Biologics Corp. Common Stock

Rentabilität für sechs Monate: -19.79%
Dividendenrendite: 0.00%

Aktionsplan Turnstone Biologics Corp. Common Stock

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Turnstone Biologics Corp. Common Stock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.

weitere details
The company was founded in 2014 and is based in LA Jolla, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2023-07-21
ISIN US90042W1009
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://turnstonebio.com
Цена ао 0.4
Preisänderung pro Tag: 0% (0.377)
Preisänderung pro Woche: +0.5333% (0.375)
Preisänderung pro Monat: +1.4% (0.3718)
Preisänderung über 3 Monate: -19.27% (0.467)
Preisänderung über sechs Monate: -19.79% (0.47)
Preisänderung pro Jahr: -86.54% (2.8)
Preisänderung seit Jahresbeginn: -16.22% (0.45)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.78 8
P/BV 0.3638 10
P/E 0 0
EV/EBITDA 0.2247 10
Gesamt: 6

Effizienz

Name Bedeutung Grad
ROA, % -92.63 0
ROE, % -108.87 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0164 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -80.94 0
Rentabilität Ebitda, % -310.74 0
Rentabilität EPS, % -304.99 0
Gesamt: 1
Weitere Details

Institutionen Volumen Aktie, %
Orbimed Advisors LLC. 3099265 13.42
FMR, LLC 2546661 11.02
Bank of America Corporation 914058 3.96
Point72 Asset Management, L.P. 833333 3.61
Eventide Asset Management LLC 708317 3.07
Citadel Advisors Llc 688468 2.98
PFM Health Sciences, LP 633313 2.74
72 Investment Holdings, LLC 549981 2.38
Sectoral Asset Management, Inc. 517648 2.24
Blackrock Inc. 301925 1.31

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Sammy J. Farah M.B.A., Ph.D. President, CEO & Director 678.51k 1973 (52 Jahr)
Dr. Venkat Ramanan Ph.D. Chief Financial Officer 346.13k 1970 (55 Jahre)
Dr. Michael F. Burgess M.D., MBChB, Ph.D. Interim Chief Medical Officer & Executive Director 212.69k 1963 (62 Jahr)
Ms. Saryah Azmat Chief Business Officer 479.73k 1990 (35 Jahre)
Dr. Vijay Chiruvolu M.B.A., Ph.D. Interim Chief Technology Officer N/A 1962 (63 Jahr)
Dr. David Stojdl Ph.D. Senior Vice President of Research & Discovery
Dr. Ines Verdon M.D. Senior Vice President of Clinical Development

Adresse: United States, LA Jolla. CA, 9310 Athena Circle - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://turnstonebio.com